secwatch.observer — SEC 8-K summary
======================================

Issuer:     Disc Medicine, Inc. (IRON)
CIK:        0001816736
Form:       8-K
Filed at:   2023-03-31T23:59:59+00:00
Accession:  0001193125-23-086710
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 5.08, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Disc Medicine reports FY2022 net loss $46.8M; cash $194.6M; bitopertin Phase 2 trials ongoing
--------------------------------------------------------------------------------

- Net loss of $46.8M for FY2022 vs $36.0M in 2021; R&D expenses $33.4M, G&A $14.0M.
- Cash and equivalents $194.6M as of Dec 31, 2022, up from $88.0M; expects to fund operations into 2025.
- Bitopertin Phase 2 BEACON (EPP/XLP) interim data expected 1H 2023; AURORA topline data by end 2023.
- DISC-0974 Phase 1b/2 in MF and NDD-CKD initiated; interim data expected end 2023.
- Annual meeting June 9, 2023; record date April 14; stockholder proposal deadline April 10.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1816736/000119312523086710/0001193125-23-086710-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1816736/000119312523086710/d463005d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-086710

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer